Ignite Creation Date:
2024-05-05 @ 10:15 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01066845
Status:
COMPLETED
Last Update Posted:
2015-10-26
First Post:
2010-02-03
Brief Title:
Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Safety and Effectiveness of Adcirca Tadalafil in Japanese Patients With Pulmonary Arterial Hypertension Open-label Non-interventional Observational Study in Japan
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the long-term safety and effectiveness of Adcirca tadalafil in Pulmonary Arterial Hypertension PAH patients in the clinical practice -focused topics-
1 To evaluate the incidence of adverse events for the patients with long-term use
2 To evaluate the incidence of adverse events of decreased blood pressure bleeding including uterine hemorrhage visual disturbance and sudden hearing loss
1 To evaluate the incidence of adverse events for the patients with long-term use
2 To evaluate the incidence of adverse events of decreased blood pressure bleeding including uterine hemorrhage visual disturbance and sudden hearing loss
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H6D-JE-TD01 | OTHER | Eli Lilly and Company | None |